Development and clinical validation of a multiplex PCR-based targeted next-generation sequencing panel for simultaneous DNA/RNA pathogen detection in respiratory tract infections: a comprehensive performance evaluation

Abstract Objectives Lower respiratory tract infections (LRTI) remain a leading cause of global morbidity and mortality, with approximately 62 % of cases lacking definitive etiological diagnoses via conventional methods. This study aimed to develop and validate a multiplex PCR-based targeted next-generation sequencing (mp-tNGS) panel for comprehensive pathogen detection in respiratory samples. Methods We conducted a combined retrospective (n=209) and prospective (n=256) study involving 465 bronchoalveolar lavage fluid (BALF) samples from patients with suspected LRTI. The mp-tNGS panel was designed to detect 277 clinically relevant pathogens, integrating simultaneous DNA/RNA co-detection and single-nucleotide polymorphism (SNP)-based contamination control. Diagnostic performance was evaluated against conventional microbiological tests (CMTs) and metagenomic next-generation sequencing (mNGS). Results The mp-tNGS assay revealed a limit of detection (LoD) of 25 copies/mL for bacteria/fungi and 50 copies/mL for viruses, with acceptable precision (intrabatch CV=9.42 %; interbatch CV=26.03 %). A novel SNP-based bioinformatics pipeline achieved exceptional discriminative performance (AUC=0.992) for distinguishing true infections from contamination. Compared with CMTs and mNGS, mp-tNGS showed superior sensitivity (93.59 %, 95 % CI: 90.81–95.73 %), particularly for viruses (AUC=0.92 vs. 0.845). The assay reliably identified fastidious pathogens (e.g., Pneumocystis jirovecii and Legionella pneumophila ) and predicted antimicrobial resistance (97.08 % concordance with phenotypic testing). Conclusions We developed an mp-tNGS panel with diagnostic performance comparable to that of mNGS. The panel integrates broad pathogen coverage, rapid turnaround time, machine learning-based false-positive reduction, and concordance with phenotypic susceptibility testing, positioning it as a promising molecular diagnostic tool for LRTI.

Authors

Institutions

Publication Details

Journal
Clinical Chemistry and Laboratory Medicine (CCLM)
Published
2026-11-12
DOI
https://doi.org/10.1515/cclm-2026-0540
Primary Topic
Bacterial Identification and Susceptibility Testing
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Development and clinical validation of a multiplex PCR-based targeted next-generation sequencing panel for simultaneous DNA/RNA pathogen detection in respiratory tract infections: a comprehensive performance evaluation

Dandan Tie, Juan Long, Li Jiang, Xiaoyan Tao et al.
Clinical Chemistry and Laboratory Medicine (CCLM)
Bacterial Identification and Susceptibility Testing
article

Development and clinical validation of a multiplex PCR-based targeted next-generation sequencing panel for simultaneous DNA/RNA pathogen detection in respiratory tract infections: a comprehensive performance evaluation

Dandan Tie, Juan Long, Li Jiang, Xiaoyan Tao, Junli Wang, Jie Zhang, Shenhui Yang
article en

Abstract

Abstract Objectives Lower respiratory tract infections (LRTI) remain a leading cause of global morbidity and mortality, with approximately 62 % of cases lacking definitive etiological diagnoses via conventional methods. This study aimed to develop and validate a multiplex PCR-based targeted next-generation sequencing (mp-tNGS) panel for comprehensive pathogen detection in respiratory samples. Methods We conducted a combined retrospective (n=209) and prospective (n=256) study involving 465 bronchoalveolar lavage fluid (BALF) samples from patients with suspected LRTI. The mp-tNGS panel was designed to detect 277 clinically relevant pathogens, integrating simultaneous DNA/RNA co-detection and single-nucleotide polymorphism (SNP)-based contamination control. Diagnostic performance was evaluated against conventional microbiological tests (CMTs) and metagenomic next-generation sequencing (mNGS). Results The mp-tNGS assay revealed a limit of detection (LoD) of 25 copies/mL for bacteria/fungi and 50 copies/mL for viruses, with acceptable precision (intrabatch CV=9.42 %; interbatch CV=26.03 %). A novel SNP-based bioinformatics pipeline achieved exceptional discriminative performance (AUC=0.992) for distinguishing true infections from contamination. Compared with CMTs and mNGS, mp-tNGS showed superior sensitivity (93.59 %, 95 % CI: 90.81–95.73 %), particularly for viruses (AUC=0.92 vs. 0.845). The assay reliably identified fastidious pathogens (e.g., Pneumocystis jirovecii and Legionella pneumophila ) and predicted antimicrobial resistance (97.08 % concordance with phenotypic testing). Conclusions We developed an mp-tNGS panel with diagnostic performance comparable to that of mNGS. The panel integrates broad pathogen coverage, rapid turnaround time, machine learning-based false-positive reduction, and concordance with phenotypic susceptibility testing, positioning it as a promising molecular diagnostic tool for LRTI.

Clinical Chemistry and Laboratory Medicine (CCLM)
University of Electronic Science and Technology of China (CN), Sichuan Provincial Hospital of Traditional Chinese Medicine (CN)
Good health and well-being
Bacterial Identification and Susceptibility Testing
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon